Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

2015 ◽  
Vol 94 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Jairam R. Eswara ◽  
Niall M. Heney ◽  
Chin-Lee Wu ◽  
W. Scott McDougal
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Advanced Disease ◽  
Chemical Exposure ◽  
Small Cell ◽  
Cancer Specific Survival ◽  
Entire Cohort ◽  
Aggressive Disease ◽  
Carcinoma Of The Bladder

Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p = 0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy.

Locoregional Small Cell Carcinoma of the Bladder: Clinical Characteristics and Treatment Patterns

2014 ◽  
Vol 191 (2) ◽  
pp. 329-334 ◽  
Author(s):  
Sanjay G. Patel ◽  
C.J. Stimson ◽  
Harras B. Zaid ◽  
Matthew J. Resnick ◽  
Michael S. Cookson ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Clinical Characteristics ◽  
Treatment Patterns ◽  
Small Cell ◽  
Carcinoma Of The Bladder

scholarly journals A Case of Primary Small-Cell Carcinoma of the Bladder

2016 ◽  
Vol 9 (3) ◽  
pp. 574-579 ◽  
Author(s):  
Ashita Ono ◽  
Yosuke Hirasawa ◽  
Mitsumasa Yamashina ◽  
Naoto Kaburagi ◽  
Takashi Mima ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Small Cell Carcinoma ◽  
Distant Metastasis ◽  
Small Cell ◽  
Common Type ◽  
Cell Of Origin ◽  
Carcinoma Of The Bladder

Primary small-cell carcinoma arising from the bladder (SmCCB) is uncommon. It differs from urothelial carcinoma (UC), the most common type of bladder cancer, with respect to its cell of origin, biology, and prognosis. Biologically, prostatic SmCCB is much more aggressive than UC, and the prognosis for cases with distant metastasis is especially poor. We report here a case of primary SmCCB (cT3bN1M0) treated with radical cystectomy.

SMALL CELL CARCINOMA OF THE BLADDER MIMICKING A GYNECOLOGICAL TUMOR

2001 ◽  
Vol 165 (1) ◽  
pp. 186-187 ◽  
Author(s):  
LI-JEN WANG ◽  
YON-CHEONG WONG ◽  
YANG-JEN CHIANG ◽  
CHI-JEN CHEN
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Gynecological Tumor ◽  
Carcinoma Of The Bladder

scholarly journals First Case of Cellular Cannibalism in Small-Cell Carcinoma of the Bladder Detected in Peripheral Blood

2019 ◽  
Vol 39 (4) ◽  
pp. 400-402
Author(s):  
Hyein Kang ◽  
Do-Hoon Kim ◽  
Wonmok Lee ◽  
Jungsook Ha ◽  
Namhee Ryoo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Peripheral Blood ◽  
Small Cell ◽  
First Case ◽  
Carcinoma Of The Bladder

scholarly journals Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Eva Van Bos ◽  
Peter Dekuyper ◽  
Charlotte Gabriel ◽  
Marjan Waterloos ◽  
Anthony Van Baelen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Low Dose ◽  
Specific Antigen ◽  
Small Cell ◽  
Carcinoma Of The Prostate ◽  
Low Dose Rate ◽  
Low Dose Rate Brachytherapy

Abstract Background Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy. Case presentation This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy. Conclusion Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.

Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 312-312 ◽  
Author(s):  
Faraj El-Gehani ◽  
Arunee Dechaphunkul ◽  
Muna Kamal ◽  
Danielle Pertschy ◽  
Kurian Joseph ◽  
...  
Keyword(s):  
Supportive Care ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Retrospective Chart Review ◽  
Concurrent Chemotherapy ◽  
Small Cell ◽  
Entire Group ◽  
Entire Cohort ◽  
Limited Stage ◽  
Stage Disease

312 Background: Small cell carcinoma (SCC) of the genitourinary (GU) tract is rare and there is no standard treatment strategy for managing these patients. The objective of this study is to report the clinical experience and management of patients with SCC of the GU tract, treated in the Cross Cancer Institute, Edmonton, AB, Canada from 1999 to 2009. Methods: A retrospective chart review of all patients diagnosed with SCC of the GU tract between 1999 to 2009 was undertaken. Data was collected on demographics, clinical and pathological characteristics, and patient outcomes. Results: Fifty-eight patients were identified with primary sites as follows: urinary bladder (UB) 35 (60%), prostate 17 (29%) and upper urinary tract (UUT) 6 (11%). Mean age for the entire group was 68 years; 12/58 were female and 46/58 were male. Sixty-six percent (37/58) had pure SCC; the rest had mixed histology. Seventy percent (41/58) were positive for at least one neuroendocrine marker. Overall, 27/58 had limited stage disease, 25/58 had extensive disease and six were unknown. Treatment of limited stage patients was 10/27 (37%) concurrent chemotherapy with radiation, 5/27 (19%) surgery +/- adjuvant chemotherapy, 5/27 (19%) chemotherapy alone, 2/27 (7%) radiation alone and 5/27 (19%) supportive care only. For extensive stage patients, 5/25 (20%) received chemotherapy alone, 3/25 (12%) received radiation alone, 4/25 (16%) received RT and chemotherapy, 4/25 (16%) surgery alone and 9/25 (36%) supportive care only. One patient with limited stage disease received prophylactic cranial irradiation. Despite this, only one patient in the entire cohort presented with brain metastases as the site of initial relapse. Median survival for the entire cohort was 24 months (28 months for limited stage disease and 7 months for extensive). Prostate patients tended to do worse, with a survival of only eight months. Conclusions: SCC of the GU tract is aggressive with an overall poor prognosis. As there is no standard of care for these patients, they are treated according to local protocols. Further efforts should be made to develop more effective treatments and the role of PCI should be investigated in the setting of a clinical trial, in conjunction with other extrapulmonary SCCs.

Primary Small Cell Carcinoma of the Bladder

1995 ◽  
pp. 1820-1822 ◽  
Author(s):  
Sten Holmang ◽  
Goran Borghede ◽  
Sonny L. Johansson
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Bladder
Sign in / Sign up

Export Citation Format

Share Document